Suzanne P. MacFarland, MD, is an attending physician in the Division of Oncology and a member of the Cancer Predisposition Program at Children's Hospital of Philadelphia (CHOP). She specializes in treating children with pediatric cancer predisposition syndromes including Li-Fraumeni Syndrome and pediatric polyposis syndromes such as Juvenile Polyposis Syndrome, Familial Adenomatous Polyposis, Peutz-Jeghers syndrome, and PTEN hamartoma tumor syndrome. She is also a member of the Solid Tumor team, specializing in the diagnosis and management of pediatric solid tumors, with a focus on liver tumors.
Her research is focused primarily on understanding the cause and improving the surveillance in these predisposition syndromes, particularly in pediatric polyposis syndromes and Li-Fraumeni syndrome. She hopes that with improved methods of surveillance we can detect tumors at an earlier stage where treatment may be less intensive. “Because they are at risk of further cancers down the line, we need to be thoughtful about their treatment and surveillance,” she says.
She chose to specialize in pediatric oncology out of a heartfelt desire to help children and families through some of life’s most challenging moments. She believes CHOP is particularly well-equipped to support children and their families, through many resources developed to treat each patient as an individual and to recognize their needs in the context of their family and community. “I hope every family leaves their first appointment at CHOP feeling like they have a team that is on their side,” she says.
Dr. MacFarland earned her medical degree from the New York University School of Medicine in 2011. She completed her residency in Pediatrics as well as a fellowship in Pediatric Hematology/Oncology at CHOP in 2017.
She has won several awards for her work and patient care during her tenure at CHOP, including the Teddy Beddrossian Compassionate Care Award (2013), Senior Resident Humanitarian Award (2014) and the Pediatric Fellowship Teaching Award (2015). Dr. MacFarland also serves on the Hematology/Oncology Fellowship Committee and the Pediatric Intern Selection Committee. She is also the co-founder of the Spirituality in Medicine discussion group.
In addition to seeing patients she is also an assistant professor in the Division of Oncology, Department of Pediatrics at the University of Pennsylvania’s Perelman School of Medicine.
Currently, Dr. MacFarland’s research efforts are focused on pediatric polyposis syndromes and Li-Fraumeni syndrome. She says she is particularly interested in work that can improve methods of diagnosis as well as potential preventative measures for patients who are at risk of cancer.
Education and Training
MD - New York University School of Medicine, New York, NY
Pediatrics - Children's Hospital of Philadelphia, Philadelphia, PA
Hematology/Oncology - Children's Hospital of Philadelphia, Philadelphia, PA
Pediatrics – American Board of Pediatrics
Titles and Academic Titles
Instructor, Division of Oncology, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
MacFarland S, Bauer AJ, Adzick NS, Surrey LF, Noyes J, Kazahaya K, Baloch Z, Mostoufi-Moab S: Disease burden and outcome in pediatric and young adults with concurrent Graves Disease and differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 103:2918-2925, 2018.
MacFarland SP, Mostoufi-Moab S, Zelley K, Mattei PA, States LJ, Bhatti TR, Duffy KA, Brodeur GM, Kalish JM. Management of adrenal masses in patients with Beckwith-Wiedemann syndrome. Management of adrenal masses in patients with Beckwith-Wiedemann syndrome. Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26432. Epub 2017 Jan 9.
Iyer R, Wehrmann L, Golden RL, Naraparaju K, Croucher JL, MacFarland SP, Guan P, Kolla V, Wei G, Cam N, Li G, Hornby Z, Brodeur GM. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Letters. 2016; 372(2), 179-86.
MacFarland SP, Hartung H. Pancytopenia in a patient with methylmalonic acidemia. Blood 2015; 125(11), 1840.
2016-present, Children’s Hospital of Philadelphia Fellows Association, Co-Chair
Leadership and Memberships
2015-present, American Society of Clinical Oncology
2015-present, American Association of Cancer Research
2015-present, Advances in Neuroblastoma Research
2014-present, Children’s Oncology Group
Patient Experience Ratings
About the Patient Experience Rating System
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.